Obesity (BMI ≥30): History of Treatment Over Decades

The Pre-Pharmacology Era: Dietary and Behavioral Approaches (1900s, 1940s)

Before any drug reached a prescription pad, clinicians treated obesity almost entirely through calorie restriction and behavioral change. The dominant model from the early twentieth century through the 1940s held that obesity was a failure of willpower, not a disease, and that simply eating less would correct it.

Low-Calorie Diets as the Default Standard

The 1,200 kcal/day diet gained traction in the 1920s following the work of endocrinologist Lulu Hunt Peters, whose 1918 book "Diet and Health" introduced calorie counting to a mainstream audience. Very-low-calorie diets (VLCDs) of 400 to 800 kcal/day appeared in clinical settings by the 1930s, though metabolic adaptation and rebound weight gain were already recognized problems.

The Role of Early Endocrinology

Thyroid extract was prescribed widely in the early twentieth century based on the observation that hypothyroidism caused weight gain. Doses were poorly standardized, cardiac adverse effects were common, and controlled evidence was absent. By the 1940s, the practice had largely fallen out of favor, a pattern that would repeat itself with multiple drug classes over the following fifty years.

The Amphetamine and Stimulant Era (1940s, 1970s)

The pharmacological treatment of obesity began in earnest with amphetamines. Benzedrine (amphetamine sulfate), originally synthesized in 1927, was repurposed for appetite suppression after clinicians noted weight loss in patients using it for other indications.

Rise of Amphetamine Prescribing

By the 1950s, amphetamine and its congeners were among the most commonly prescribed drugs in the United States. Short-term weight loss was real, averaging 3 to 5 percent of body weight in open-label series, but dependence, cardiovascular toxicity, and rebound obesity after discontinuation were consistent findings. The FDA began tightening scheduling controls through the 1960s, and the Controlled Substances Act of 1970 placed amphetamines in Schedule II, effectively ending their routine use for obesity [1].

Phentermine Survives the Era

Phentermine, a structurally related but less addictive sympathomimetic, received FDA approval for short-term obesity treatment in 1959 and remains approved today [2]. Its durability is notable: sixty-five years of clinical use with a safety profile well enough characterized that current Endocrine Society guidelines list it as an option for patients who cannot access or tolerate newer agents.

The Fen-Phen Disaster

The combination of fenfluramine and phentermine ("fen-phen") produced average weight loss of 10.6 percent in a 34-week randomized trial published by Weintraub et al. In 1992. Adoption was rapid. By 1996, prescriptions for the combination exceeded 18 million annually in the US. FDA withdrew fenfluramine and dexfenfluramine from the market in September 1997 after echocardiographic studies detected valvular heart disease in up to 32 percent of exposed patients [3]. The withdrawal reshaped regulatory expectations for antiobesity drugs for the next fifteen years and prompted the FDA to require dedicated cardiovascular outcomes trials for new weight-loss agents.

Surgery Enters the Frame (1950s, 1990s)

Bariatric surgery predates modern pharmacotherapy by several decades in its evidence base. The jejunoileal bypass, introduced in the 1950s, produced large weight losses but caused severe complications including liver failure and electrolyte disorders, and was largely abandoned by the 1980s [4].

Gastric Bypass Becomes the Reference Procedure

Roux-en-Y gastric bypass (RYGB), first described by Edward Mason in 1966, became the benchmark against which other procedures were measured. The Swedish Obese Subjects (SOS) study enrolled 4,047 patients between 1987 and 2001 and followed them for up to twenty years. At two years, surgically treated patients had lost a mean of 23 percent of body weight versus 0.1 percent in the matched control group. At twenty years, mean sustained weight loss remained 18 percent in the surgical group, and the study documented a 29 percent reduction in all-cause mortality [5].

Laparoscopy Expands Access

Laparoscopic adjustable gastric banding (LAGB) gained FDA approval in 2001. The less-invasive approach broadened eligibility and reduced short-term operative risk, though ten-year reoperation rates reached 40 to 50 percent in some series [6]. Sleeve gastrectomy, now the most commonly performed bariatric procedure in the United States, emerged in the late 1990s as a first-stage procedure and was recognized as a standalone operation by the American Society for Metabolic and Bariatric Surgery in 2012.

The Orlistat and Sibutramine Window (1999 to 2010)

After the fen-phen withdrawal, regulatory agencies required more rigorous cardiovascular safety data. Two drugs filled the post-1997 void, with very different endings.

Orlistat: The First Long-Term FDA-Approved Oral Agent

Orlistat (Xenical, Roche) inhibits pancreatic lipase, blocking absorption of approximately 30 percent of dietary fat. FDA approval came in April 1999 for chronic weight management [7]. The XENDOS trial (N=3,305, four years) showed orlistat plus lifestyle intervention reduced weight by 5.8 kg versus 3.0 kg with placebo and cut the incidence of type 2 diabetes by 37.3 percent in patients with impaired glucose tolerance [8]. Gastrointestinal side effects, particularly fecal urgency and oil spotting, led to high discontinuation rates in real-world practice. A 60 mg over-the-counter version (Alli) received FDA clearance in 2007.

Sibutramine Withdrawn in 2010

Sibutramine (Meridia, Abbott) was approved in 1997 as a norepinephrine-serotonin reuptake inhibitor producing 5 to 8 percent weight loss. The SCOUT trial (N=10,744), a cardiovascular outcomes study mandated post-approval, found a 16 percent increase in the composite of nonfatal myocardial infarction and nonfatal stroke versus placebo in high-risk patients. The FDA withdrew sibutramine in October 2010 [9].

Combination Pharmacotherapy and the 2012 to 2014 Approvals

Between 2010 and 2014, the FDA approved three new antiobesity agents, the most concentrated burst of approvals the field had seen. All three required cardiovascular outcomes data or post-marketing commitments.

Qsymia: Phentermine Plus Topiramate Extended-Release

FDA approved phentermine/topiramate ER (Qsymia, Vivus) in July 2012. The CONQUER trial (N=2,487, 56 weeks) reported weight loss of 9.8 percent with the high dose versus 1.2 percent with placebo [10]. The combination carries a teratogenicity risk (oral clefts) and requires a Risk Evaluation and Mitigation Strategy (REMS) program for women of reproductive potential.

Belviq: Lorcaserin's Brief Career

Lorcaserin (Belviq, Arena/Eisai), a selective serotonin 2C receptor agonist, received approval in June 2012 after producing 5.8 percent mean weight loss in BLOOM (N=3,182, 52 weeks). The cardiovascular outcomes trial CAMELLIA-TIMI 61 (N=12,000) confirmed no increase in major adverse cardiac events, but a post-marketing safety study found a numerically higher rate of cancer in the lorcaserin arm. FDA withdrew lorcaserin in February 2020 [11].

Contrave: Naltrexone Plus Bupropion SR

Naltrexone/bupropion SR (Contrave, Currax) received FDA approval in September 2014. The COR-I trial (N=1,742, 56 weeks) showed 6.1 percent weight loss versus 1.3 percent with placebo [12]. Cardiovascular outcomes data collection was interrupted early by a protocol breach; the trial was formally terminated and the outcomes question remains only partially resolved.

The GLP-1 Receptor Agonist Revolution (2014, Present)

The most consequential shift in obesity pharmacotherapy began with a diabetes drug. GLP-1 receptor agonists were developed for glycemic control, but weight loss emerged as a consistent, dose-dependent benefit that eventually became the primary indication for the class.

Liraglutide 3.0 mg: The First GLP-1 Approved for Obesity

Liraglutide (Saxenda, Novo Nordisk) at 3.0 mg daily received FDA approval for chronic weight management in December 2014 [13]. The SCALE Obesity trial (N=3,731, 56 weeks) demonstrated 8.0 percent mean weight loss versus 2.6 percent with placebo, and 63.2 percent of liraglutide-treated patients achieved at least 5 percent weight loss [14]. Nausea affected roughly 39 percent of participants, a side-effect profile that became the class benchmark for tolerability comparisons.

Semaglutide 2.4 mg: The STEP Program

Weekly subcutaneous semaglutide 2.4 mg (Wegovy, Novo Nordisk) received FDA approval in June 2021. The STEP-1 trial (N=1,961, 68 weeks) produced 14.9 percent mean weight loss versus 2.4 percent with placebo (P<0.0001), with 86.4 percent of semaglutide participants achieving at least 5 percent weight loss [15]. STEP-4 (N=803) demonstrated that discontinuing semaglutide after 20 weeks led to regain of two-thirds of lost weight within 48 weeks, establishing chronic therapy as the clinical expectation rather than a short course [16].

The SELECT cardiovascular outcomes trial (N=17,604, mean follow-up 33.9 months) reported a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo in patients with established cardiovascular disease but without diabetes, leading to an FDA label expansion in March 2024 [17].

Tirzepatide: Dual GIP/GLP-1 Agonism

Tirzepatide (Zepbound, Eli Lilly) acts simultaneously on glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA approval for chronic weight management came in November 2023. The SURMOUNT-1 trial (N=2,539, 72 weeks) showed mean weight loss of 20.9 percent at the 15 mg dose versus 3.1 percent with placebo, with 57.9 percent of participants achieving at least 20 percent weight loss [18]. These figures represent the largest weight reductions ever reported in a pharmacotherapy trial without surgical intervention.

The table below summarizes approved antiobesity pharmacotherapies across decades, weight-loss benchmarks, and current status.

| Drug | Approval Year | Trial Weight Loss | Current Status | |---|---|---|---| | Phentermine | 1959 | 3 to 5% (short-term series) | Approved (short-term) | | Orlistat 120 mg | 1999 | 5.8 kg at 4 years (XENDOS) | Approved | | Phentermine/topiramate ER | 2012 | 9.8% at 56 weeks (CONQUER) | Approved | | Naltrexone/bupropion SR | 2014 | 6.1% at 56 weeks (COR-I) | Approved | | Liraglutide 3.0 mg | 2014 | 8.0% at 56 weeks (SCALE) | Approved | | Lorcaserin | 2012 | 5.8% at 52 weeks (BLOOM) | Withdrawn 2020 | | Semaglutide 2.4 mg | 2021 | 14.9% at 68 weeks (STEP-1) | Approved | | Tirzepatide 15 mg | 2023 | 20.9% at 72 weeks (SURMOUNT-1) | Approved |

How Guidelines Evolved Alongside the Evidence

Treatment guidelines do not simply follow drug approvals. They often lag behind the trial data by years, and the obesity field is a clear example.

The 1998 NIH Clinical Guidelines

The first major US guideline, published by the National Heart, Lung, and Blood Institute in 1998, recommended a calorie deficit of 500 to 1,000 kcal/day as the primary intervention, with pharmacotherapy reserved for patients with BMI <30 and comorbidities or BMI <35 without comorbidities [19]. The document set the framework that would persist, largely unchanged, for fifteen years.

AHA/ACC/TOS 2013 Guideline

The 2013 AHA/ACC/TOS Guideline on the Management of Overweight and Obesity was the first major revision. It stated: "The evidence supports the use of approved weight-loss medications as an adjunct to lifestyle intervention for patients who have a BMI <30 or greater with comorbidity or a BMI <35 or greater." [20] The 2013 document explicitly recognized obesity as a chronic disease requiring long-term management, a significant conceptual shift from the earlier short-course pharmacotherapy model.

Endocrine Society 2015 Clinical Practice Guideline

The Endocrine Society guideline published in 2015 in the Journal of Clinical Endocrinology and Metabolism stated: "We recommend using medications only as an adjunct to lifestyle modification in patients with BMI <30 or with BMI between 27 and 30 with weight-related comorbidities." [21] It also recommended choosing drug therapy based on individual comorbidity profiles rather than a single first-line agent, a practical shift that acknowledged the absence of any head-to-head superiority data among approved agents at that time.

The 2023 to 2025 Guideline Update Cycle

The American Gastroenterological Association issued a clinical practice guideline in 2022 recommending GLP-1 receptor agonists over older antiobesity medications, citing superior weight-loss magnitude and cardiovascular safety data [22]. Multiple specialty societies are currently revising their guidelines to incorporate tirzepatide data and the SELECT cardiovascular outcomes findings.

The Shifting Disease Model: From Willpower to Neurobiology

The clinical framing of obesity changed substantially across the decades covered here. Early treatment models centered on patient behavior. By the 2000s, accumulating neurobiological evidence shifted the field toward a model that recognized central appetite regulation, hypothalamic signaling, and adipose-tissue endocrinology as primary drivers of weight gain and regain.

Leptin Discovery and Its Clinical Limits

The discovery of leptin in 1994 by Jeffrey Friedman's group at Rockefeller University was expected to produce a pharmacological breakthrough. Leptin deficiency causes severe early-onset obesity, and exogenous leptin corrects it in those rare monogenic cases [23]. In common obesity, however, circulating leptin levels are already high and central resistance blunts any therapeutic signal. Leptin monotherapy trials in common obesity showed only modest 1 to 3 kg weight loss at pharmacological doses, closing that particular avenue.

Set-Point Physiology and the Case for Chronic Therapy

Energy balance research from the 1990s through the 2010s consistently showed that weight loss triggers compensatory increases in appetite and reductions in resting metabolic rate. The Minnesota Starvation Experiment (Keys, 1950) first documented metabolic adaptation; later work by Rosenbaum et al. (2008) in NEJM quantified the hormonal mediators [24]. This evidence base directly supports the conclusion that any effective obesity pharmacotherapy must be maintained indefinitely, a position now reflected in FDA labeling for semaglutide and tirzepatide and in the 2013 AHA/ACC/TOS guideline language.

Pipeline and Near-Future Directions

Several agents in late-stage development may extend the weight-loss ceiling beyond what tirzepatide currently achieves.

Triple Agonists and Novel Targets

Retatrutide, a GIP/GLP-1/glucagon triple agonist, produced mean weight loss of 24.2 percent at 48 weeks in a phase 2 trial (N=338) published in NEJM in 2023 [25]. Cagrilintide combined with semaglutide (CagriSema) showed 15.6 percent weight loss at 32 weeks in a phase 2 study, with a phase 3 program underway. Amylin analogues, orexin antagonists, and hypothalamic circuit modulators are in earlier development.

Oral GLP-1 Formulations

Oral semaglutide (Rybelsus) is already approved at 14 mg daily for type 2 diabetes. Higher-dose oral formulations for obesity (up to 50 mg daily) are in phase 3 trials. Removal of the injection barrier may substantially expand the patient population that engages with pharmacotherapy.

What Seventy Years of Obesity Treatment Data Teach Clinicians

The through-line across seven decades is consistent: the treatments that work best in the short term have often proven unsafe or unsustainable at scale, while the treatments with the most durable long-term evidence (bariatric surgery and, now, GLP-1 receptor agonists) require ongoing engagement rather than a fixed treatment course.

The Weight Regain Problem Persists

Diet-only interventions produce mean weight loss of 5 to 10 percent, but studies tracking patients for five or more years show that 80 percent or more regain the majority of lost weight without sustained behavioral or pharmacological support [26]. Bariatric surgery produces the most durable results in any controlled data set, with SOS showing 18 percent mean weight loss maintained at twenty years [5].

Cardiovascular Risk Reduction Is Now a Documented Outcome

The SELECT trial finding of a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients without diabetes was a first: a randomized trial showing that an antiobesity drug reduces hard cardiovascular endpoints in a population defined by obesity rather than by a metabolic complication [17]. That result shifts the clinical calculus from "treat to reduce weight" toward "treat to reduce mortality risk."

The current FDA label for semaglutide 2.4 mg lists a starting dose of 0.25 mg weekly, titrated over 16 to 20 weeks to the 2.4 mg maintenance dose, a protocol designed specifically to minimize the nausea and vomiting that drove discontinuation in earlier GLP-1 trials.